Artwork

Innhold levert av Clinical Care Options, LLC and Clinical Care Options. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Clinical Care Options, LLC and Clinical Care Options eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
Player FM - Podcast-app
Gå frakoblet med Player FM -appen!

ROS1-Alterations and Molecular Testing in Advanced NSCLC

16:28
 
Del
 

Manage episode 436715992 series 3256997
Innhold levert av Clinical Care Options, LLC and Clinical Care Options. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Clinical Care Options, LLC and Clinical Care Options eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

In this episode, listen to Alice T. Shaw, MD, PhD, and Jessica J. Lin, MD, share their thoughts on the current understanding of ROS1 rearrangements in non-small-cell lung cancer tumor biology and its implications for molecular testing and treatment selection including:

  • ROS1-gene fusions in advanced lung cancer
  • ROS1 testing recommendations with DNA NGS, RNA NGS, FISH break apart assay, and IHC
  • Comparative specificity of ROS1 and ALK targeting tyrosine kinase inhibitors
  • Advantages of RNA- vs DNA-based next-generation sequencing

Program faculty:

Jessica J. Lin, MD
Attending Physician
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Alice T. Shaw, MD, PhD
Chief, Strategic Partnerships
Attending Physician, Thoracic Oncology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

Resources:

To download the slides associated with this podcast discussion, please visit the program page

  continue reading

185 episoder

Artwork
iconDel
 
Manage episode 436715992 series 3256997
Innhold levert av Clinical Care Options, LLC and Clinical Care Options. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Clinical Care Options, LLC and Clinical Care Options eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

In this episode, listen to Alice T. Shaw, MD, PhD, and Jessica J. Lin, MD, share their thoughts on the current understanding of ROS1 rearrangements in non-small-cell lung cancer tumor biology and its implications for molecular testing and treatment selection including:

  • ROS1-gene fusions in advanced lung cancer
  • ROS1 testing recommendations with DNA NGS, RNA NGS, FISH break apart assay, and IHC
  • Comparative specificity of ROS1 and ALK targeting tyrosine kinase inhibitors
  • Advantages of RNA- vs DNA-based next-generation sequencing

Program faculty:

Jessica J. Lin, MD
Attending Physician
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Alice T. Shaw, MD, PhD
Chief, Strategic Partnerships
Attending Physician, Thoracic Oncology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

Resources:

To download the slides associated with this podcast discussion, please visit the program page

  continue reading

185 episoder

Tüm bölümler

×
 
Loading …

Velkommen til Player FM!

Player FM scanner netter for høykvalitets podcaster som du kan nyte nå. Det er den beste podcastappen og fungerer på Android, iPhone og internett. Registrer deg for å synkronisere abonnement på flere enheter.

 

Hurtigreferanseguide

Copyright 2024 | Sitemap | Personvern | Vilkår for bruk | | opphavsrett